Latest News - Merck
Top Corporates Hub
Merck
Merck: receives ACIP recommendation for Enflonsia
27.06.2025 05:37
Merck announces that the CDC's Advisory Committee on Immunization Practices has voted in favor of recommending Enflonsia for the prevention of respiratory infections caused by RSV in infants under 8...
Acip Recommends Use of Merck's Enflonsia for Prevention of Respiratory Syncytial Virus
26.06.2025 15:20
Merck announced the U.S. Centers for Disease Control and Prevention Advisory Committee on Immunization Practices voted to recommend ENFLONSIA?? as an option for the prevention of respiratory...
ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season
26.06.2025 13:40
ENFLONSIA is the first and only RSV preventive option for administration to infants using the same dose regardless of weightOrdering will begin in July, with shipments delivered before the start of...
Europe Proteomics Research Report 2025: Market Insights, Competitive Landscape and Forecasts 2024-2034 Featuring Biognosys, DiaSorin, Merck, Oxford Expression Technologies
26.06.2025 13:11
The Europe proteomics market is expected to rise to $27.43 billion by 2034 from $8.77 billion in 2024, with a CAGR of 12.07%. Driving this growth are advancements in mass spectrometry and next-gen sequencing technologies enhancing protein analysis precision. The increased focus on personalized healthcare, catalyzed by biomarker discovery and disease profiling, amplifies demand. Support from EU funding, public-private partnerships, and strategic alliances further propels market expansion. Europe'
US CDC panel broadly recommends flu shots free from thimerosal
26.06.2025 12:59
The external committee advising theU.S. Centers for Disease Control and Prevention on vaccinepolicy voted that all adults in the country receive a seasonalflu shot in single-dose forms that are...
2 Stocks Too Cheap to Ignore at These Prices
26.06.2025 10:45
Alphabet can overcome legal headwinds and continue to perform well in the long term. Merck should be able to remain a leader in oncology despite mounting competition. Let's consider two stocks that meet these criteria: Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL), and Merck (NYSE: MRK).
Kennedy's US vaccine panel backs preservative-free shot despite safety evidence
26.06.2025 09:16
U.S. Health Secretary Robert F.Kennedy Jr.'s newly revamped vaccine advisory panel voted onThursday to recommend Americans receive seasonal influenza shotsthat are free from the mercury-based...
Kennedy's new US vaccine panel backs thimerosal-free flu vaccines
26.06.2025 09:16
U.S. Health Secretary Robert F.Kennedy Jr.'s newly revamped vaccine advisory panel voted onThursday to recommend Americans receive seasonal influenza shotsthat are free from the mercury-based...
Kennedy's new US vaccine panel backs Merck's RSV drug for infants
26.06.2025 09:16
U.S. Health Secretary Robert F.Kennedy Jr.'s newly revamped vaccine advisory panel voted onThursday to recommend use of Merck's recently approvedRSV antibody drug for infants 8 months or younger...
Kennedy's US vaccine panel votes in favor of Merck's RSV antibody drug
26.06.2025 09:16
U.S. Health Secretary Robert F.Kennedy Jr.'s newly revamped vaccine advisory panel voted onThursday for recommending use of Merck's RSV antibodydrug for infants 8 months or younger whose mothers...
US CDC panel votes in favor of Merck's RSV antibody drug
26.06.2025 09:16
An advisory panel of the U.S.Centers for Disease Control and Prevention on Thursdayrecommended the use of Merck's respiratory syncytialvirus therapy, Enflonsia, for infants 8 months or younger,...
Kennedy remake of CDC vaccine panel has US insurers reassessing sources of expertise
25.06.2025 06:02
Health insurers areconsidering new expert sources to help determine which vaccinesto pay for as anti-vaccine activist and now U.S. HealthSecretary Robert F. Kennedy Jr. begins to revise...
Kennedy's US vaccine panel set to break norms meant to ensure sound policy
25.06.2025 06:01
* Vaccine panel meeting changes raise concerns amongexperts,former members * Experts raise concerns over thimerosal presentation byanti-vaccine group member ...
Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention
24.06.2025 06:46
Merck , known as MSD outside of the United States and Canada, today announced that scientific and commercial team leaders will host a virtual investor event where they will give an overview of the...
Merck Poised to Deliver Strong Results and Steady Dividend Growth
24.06.2025 02:46
Merck & Co., Inc. (NYSE:MRK) is one of the Best Dividend Leaders to Buy Now. Merck & Co., Inc. (NYSE:MRK) has struggled over the past year, with its stock falling nearly 40%, partly due to concerns about rising competition from therapies still in development, such as Summit Therapeutics’ ivonescimab. However, the company is working on […]
Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)
23.06.2025 10:45
RAHWAY, N.J., June 23, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 HYPERION study evaluating WINREVAIR™ (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional class (FC) II or III at intermediate or high risk of disease progression. HYPERION met its primary endpoint of time to clinica
Merck's Pulmonary Arterial Hypertension Drug Meets Primary Endpoint
23.06.2025 09:22
By Adriano Marchese Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints. On Monday, the pharmaceutical company said it has received...
Merck: new positive Phase 3 results in PAH
23.06.2025 08:29
Merck reported positive Phase 3 results on Monday in patients with pulmonary arterial hypertension in Group 1 and Functional Class II or III according to the World Health Organization or at high...
Merck Announces Phase 3 HYPERION Study of Winrevair Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension
23.06.2025 07:35
Merck announced positive topline results from the Phase 3 HYPERION study evaluating WINREVAIR?? versus placebo in recently diagnosed adults with pulmonary Arterial hypertension functional class II...
Why CareTrust, Merck, And Allete Are Winners For Passive Income
20.06.2025 12:00
Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. CareTrust, Merck, and Allete have rewarded shareholders for years and recently announced dividend increases. These companies ...